Atopic dermatitis (AD) is a chronic disease driven by persistent underlying inflammation even in nonlesional or normal looking skin2–4

An imbalanced immune system, together with epidermal abnormalities, drive Type 2 inflammation2–4

IL-4 and IL-13 are key Th2 cytokines involved in AD2–4

These cytokines modulate the immune response, drive persistent inflammation and contribute to worsening barrier dysfunction2–4

UNDERLYING TYPE 2 INFLAMMATION

Learn more about the pathophysiology of AD

Moderate-to-severe AD has a major impact on patients’ quality of life7

It’s important to understand the effect that AD has on patients’ lives.

Mode of action DUPIXENT

Have questions about how DUPIXENT works?





Find out more

Overview of AD

Find out more about how AD has a continuous inflamation cycle.




Find out more

Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.



Find out more

    AD, atopic dermatitis; IL, interleukin; Th, T-helper cells.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Leung DYM, et al. J Clin Invest. 2004;113(5):651–657.
    3. Suárez-Fariñas M, et al. J Allergy Clin Immunol. 2011;127(4):954–964.
    4. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
    5. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    6. Artis D & Spits H. Nature. 2015;517:293–301.
    7. Biedermann T, et al. Front Immunol. 2015;6:353.

MAT-IE-2101040(v4.0) | Date of preparation: February 2022